Publication | Closed Access

Amentoflavone mitigates doxorubicin-induced cardiotoxicity by suppressing cardiomyocyte pyroptosis and inflammation through inhibition of the STING/NLRP3 signalling pathway

InflammationDoxorubicin-induced CardiotoxicityHeart FailureAnti-inflammatoryCardiovascular DiseaseMedicineLipid PeroxidationImmunologyCardiovascular PharmacologyChronic InflammationCell DeathPharmacotherapyCardiovascular ToxicityPharmacologyCardiomyocyte PyroptosisOxidative Stress